Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Animal Model and Predictive Test Developed for Preeclampsia

By LabMedica International staff writers
Posted on 28 Oct 2010
Scientists have developed a well-defined animal model of preeclampsia and a potential lab test for diagnosing the disease in people. More...
Preeclampsia is a potentially dangerous condition that sometimes occurs during pregnancy and can be fatal for both mother and fetus.

The presence of the immune system secretion Interleukin-10 (IL-10) has been linked to a successful course of pregnancy. Scientists from Brown University and Women & Infants Hospital experimented with mice genetically engineered to lack IL-10. They isolated blood serum from human patients with preeclampsia, gave a dose of it to the mice, and the rodents developed preeclampsia symptoms. Further experiments with nonpregnant mice and pregnant wild mice confirmed that pregnant mice lacking IL-10 provide a unique and dependable model of the disease.

An animal model for preeclampsia will allow for experiments that help gain insight into the cause of the disease and its progression said Surendra Sharma, professor of pediatrics at the Warren Alpert Medical School of Brown University (Providence, RI, USA) and a research scientist at Women & Infants. One observation already made is that there is disruption in the development of "spiral arteries,” which bring nutrients to the fetus from the placenta.

This observation led to the development of a predictive test for preeclampsia. An in vitro culture of two key cell types involved in spiral artery development (endothelial cells and trophoblasts) was exposed to serum from women with normal pregnancies or to preeclampsia serum from women taken at various stages of their pregnancies.

Vasculature developed normally in the presence of serum from women with normal pregnancies whereas preeclampsia serum taken from women as early as 12 to 14 weeks into their pregnancies, about 10 to 12 weeks before they were diagnosed with preeclampsia, was able to disrupt vascular formation.

Prof. Sharma is continuing to refine the test for eventual clinical use.

Related Links:

Warren Alpert Medical School of Brown University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Clinical Informatics Platform
CLARION™
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.